Related Experiment Video
Updated: May 18, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Protein Homeostasis Screen Identifies CK2 Inhibition as a Driver of CARD9 Depletion
Aya M Kelly1, Leidy C Merselis2, Benjamin Causton2
1Lead Discovery and Optimization, Discovery and Development Sciences, Bristol Myers Squibb, 250 Water St., Cambridge, Massachusetts02141, United States.
Insights
Researchers found that inhibiting casein kinase 2 (CK2) depletes CARD9 protein, offering a new way to target this protein for autoimmune diseases. This discovery provides a potential therapeutic strategy for conditions like inflammatory bowel disease.
Area of Science:
- Immunology
- Molecular Biology
- Drug Discovery
Background:
- Card9 (caspase recruitment domain-containing protein 9) is a validated target for autoimmune diseases.
- Elevated Card9 expression is linked to increased disease risk, while lower expression offers protection.
- A rare Card9 loss-of-function variant (Card9Δ11) protects against inflammatory bowel disease.
Purpose of the Study:
- To identify novel therapeutic strategies targeting Card9, previously considered undruggable.
- To explore the role of protein homeostasis in regulating Card9 levels.
- To investigate the mechanism by which Card9 is regulated and its potential therapeutic implications.
Main Methods:
- Protein homeostasis screening to identify regulators of Card9.
- Biochemical assays to study the interaction between Card9 and casein kinase 2 (CK2).
- In vivo studies using a murine peritonitis model to assess therapeutic efficacy.
Main Results:
- Inhibition of CK2 leads to the depletion of Card9 protein in various cell types.
- CK2 directly phosphorylates Card9, promoting its destabilization.
- The Card9Δ11 variant shows reduced interaction with CK2, conferring resistance to CK2-mediated stabilization.
- CK2 inhibition effectively reduced Card9 levels in a mouse model of peritonitis.
Conclusions:
- CK2 inhibition represents a novel and unconventional approach to target Card9 for autoimmune diseases.
- This mechanism of Card9 depletion by CK2 inhibitors may explain the protective effects of the Card9Δ11 allele.
- The findings expand the understanding of kinase inhibitor functions and offer a new strategy for intractable targets.
Abstract:
CARD9 is a genetically validated target for autoimmune disease, with human expression quantitative trait loci (eQTLs) linking elevated CARD9 expression to increased disease risk and lower CARD9 expression to protection. Notably, a rare variant leading to a C-terminal truncation of CARD9 (CARD9Δ11) and subsequent loss of function confers protection against inflammatory bowel disease. Despite its therapeutic potential, CARD9 has long been considered "undruggable" as an adaptor protein with complex biology and limited chemical tools. Here, we leverage a protein homeostasis screening strategy to discover that inhibition of casein kinase 2 (CK2/CSNK2) results in the depletion of CARD9, a mechanism conserved across immortalized cell lines and primary cells. Mechanistic studies revealed that CK2 directly binds and phosphorylates CARD9 in its predicted disordered region. CK2 inhibitors prevent this protein-protein interaction, leading to CARD9 destabilization. Furthermore, the interaction between CK2 and CARD9Δ11 is significantly attenuated and resistant to CK2-mediated protein stabilization. Finally, we demonstrate therapeutic proof of concept in vivo using CK2 inhibition to deplete CARD9 in a murine peritonitis model. Our study expands the scope of cellular consequences elicited by kinase inhibition, offers an unconventional approach for engaging a therapeutically intractable target, and identifies a novel mechanism that could contribute to disease protection conferred by the CARD9Δ11 allele.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
